Inclusion Criteria

Inclusion

- Participants must have a pathologic diagnosis of prostate cancer within the past 6
months, have clinical stage T1-3 disease, PSA >= 10, Gleason score >= 8, and have
elected to undergo radical prostatectomy; those found to have detectable circulating
prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to
proceed onto the treatment phase of the protocol; pathology slides used for diagnosis
will be submitted to the SPORE tissue pathology core for review

- ECOG performance status 0-1

- Hemoglobin > 9.0gm/dl

- Platelets >= 100 K/uL

- ANC > 1000/uL

- AST (SGOT)/ALT (SGPT) < 3X upper limit of normal

- Creatinine < 2.0 mg/dl

- Total bilirubin < 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a
familial defect in bilirubin metabolism will be considered on an individual basis)

- Participants must agree not to take soy supplements

- Ability to understand and the willingness to sign a written informed consent document

- Willingness to take study agent for at least 2 weeks prior to radical prostatectomy

Exclusion

- History of venous thrombosis within past year

- Participants must not be receiving active therapy for neoplastic disorders (including
hormone or radiation therapy for prostate cancer)

- Participants may not be receiving any other investigational agents

- Known soy intolerance

- Medical conditions that, in the opinion of the investigators, would jeopardize either
the patient or the integrity of the data obtained